Company: CRISPR Therapeutics
Job title: Director, ImmunoOncology
Demetrios Kalaitzidis is a Director in the Immuno-Oncology Department at CRISPR Therapeutics. At CRISPR Therapeutics he has worked on the development of the company’s programs in hemoglobinopathies and in immune oncology. He initiated research in late 2015 on CRISPR-gene edited T cells and made key contributions in developing the company’s allogeneic CAR-T strategy, process and platform. He has played major roles in the CD19-targeted allogeneic CAR-T program, helping bring it from concept to clinical trials. His group continues to develop further advances in allogeneic CAR-T therapies using CRISPR technology. Prior to CRISPR Therapeutics he was an Instructor in Medicine at Harvard Medical School and Assistant in Biology at Massachusetts General Hospital at the Center for Regenerative Medicine and Cancer Center. He delineated the roles of multiple signal transduction pathways, including the mTOR complexes, in hematopoietic stem cell function, hemato-lymphoid development, and leukemia. He obtained his Ph.D. in Molecular and Cellular Biology and Biochemistry at Boston University demonstrating major functions for the Rel/NF-kB pathway in lymphoma.